Clinical trials: Stage I Prostate Adenocarcinoma
Adenocarcinoma of Prostate, Adenocarcinoma of the Prostate Stage I
Treatment Decision Analysis Model for Prostate Cancer: A Randomized Trial
This is a psychosocial/behavioral study and does not involve administration of any treatment or diagnostic procedures. We will use a randomized trial to test the hypothesis that a decision analysis model that provides…
- Conditions
- Adenocarcinoma of Prostate, Adenocarcinoma of the Prostate Stage I, Adenocarcinoma of the Prostate Stage II, Adenocarcinoma of the Prostate Stage III
- Trial name
- NCT02024685
- Testing
- Personalized Treatment Recommendations, Standard patient-physician counseling interaction
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Case Comprehensive Cancer Center
Prostate Cancer
Soy Supplements in Treating Patients Undergoing Surgery for Localized Prostate Cancer
RATIONALE: Dietary supplementation with soy may keep prostate cancer from growing in patients planning to undergo surgery. PURPOSE: This randomized phase II trial is studying a soy supplement to see how well it works compared to…
- Trial name
- NCT00345813
- Testing
- soy isoflavones, soy protein isolate
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Wake Forest University Health Sciences
Prostate Cancer
Radiation Therapy and Hormone Therapy in Treating Patients With Prostate Cancer
RATIONALE: Radiation therapy uses high energy x-rays to damage tumor cells. Hormone therapy combined with radiation therapy may be a more effective treatment for prostate cancer.
- Trial name
- NCT00769548
- Testing
- flutamide, goserelin acetate, low-LET photon therapy
- Volunteers
- 1,322 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Adenocarcinoma, Stage I Prostate Cancer
Stereotactic Body Radiation Therapy in Treating Patients With Low- and Intermediate-Risk Prostate Cancer
This clinical trial studies stereotactic body radiation therapy in treating patients with low- and intermediate-risk prostate cancer.
- Trial name
- NCT01737151
- Testing
- stereotactic body radiation therapy, four fraction split-course SBRT
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- Virginia Commonwealth University
Prostate Cancer
Selenium in Treating Patients Who Are Undergoing Brachytherapy for Stage I or Stage II Prostate Cancer
RATIONALE: The use of nutritional supplements, such as selenium, may stop prostate cancer from growing. Internal radiation, such as brachytherapy, uses radioactive material placed directly into or near a tumor to kill tumor…
- Trial name
- NCT00217516
- Testing
- selenium
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Roswell Park Cancer Institute
Neoplasms
Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer
Determine the safety, tolerability, pharmacokinetics, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of VIP152 (BAY 1251152) as monotherapy or in combination in patients with solid tumors and aggressive…
- Trial name
- NCT02635672
- Testing
- VIP152 (BAY 1251152), VIP152 (BAY 1251152) 30 mg, Keytruda
- Where
- 16 sites in United States, Chile and 1 more
- Volunteers
- 110 people
- Sponsor
- Vincerx Pharma, Inc.
Prostate Cancer, Adenocarcinoma of the Prostate
High-Dose Rate Brachytherapy and Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer
The first technology is called high dose rate brachytherapy. Brachytherapy is sometimes called internal radiation therapy. High dose rate brachytherapy is a procedure that involves temporarily placing radioactive material inside…
- Conditions
- Prostate Cancer, Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IIA Prostate Cancer
- Trial name
- NCT01655836
- Testing
- Brachytherapy, Stereotactic Body Radiation Therapy, Quality-of-life assessment
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Prostate Cancer
APC8015 and Bevacizumab in Treating Patients With Prostate Cancer
Phase II trial to study the effectiveness of APC8015 combined with bevacizumab in treating patients who have undergone radiation therapy and/or surgery and who have progressive prostate cancer.
- Trial name
- NCT00027599
- Testing
- bevacizumab, prostatic acid phosphatase-sargramostim fusion protein, sipuleucel-T
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Bladder Cancer, Breast Cancer
Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of…
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Gastric Cancer
- Trial name
- NCT00004065
- Testing
- tanespimycin
- Where
- 2 sites in United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer
Behavior-Based Dietary Intervention in Treating Patients With Hormone-Refractory Prostate Cancer
RATIONALE: A low-fat, high-fiber diet that includes soy protein may prevent disease progression in patients with hormone-refractory prostate cancer. Nutrition counseling may help motivate patients to follow this diet.
- Trial name
- NCT00082732
- Testing
- behavioral dietary intervention, dietary intervention, therapeutic dietary intervention
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- M.D. Anderson Cancer Center
Cancer
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
Phase I trial to study the effectiveness of trastuzumab plus R115777 in treating patients who have advanced or metastatic cancer.
- Trial name
- NCT00005842
- Testing
- trastuzumab, tipifarnib
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Androgen deprivation therapy may stop the adrenal glands from making androgens. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Trial name
- NCT01368588
- Testing
- three-dimensional conformal radiotherapy, intensity modulated radiotherapy, Brachytherapy
- Where
- 478 sites in United States, Canada and 4 more
- Volunteers
- 2,590 people
- Sponsor
- Radiation Therapy Oncology Group
Adrenocortical Carcinoma, Breast Cancer
Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Adrenocortical Carcinoma, Breast Cancer, Colorectal Cancer, Prostate Cancer
- Trial name
- NCT00003038
- Testing
- doxorubicin hydrochloride, suramin
- Where
- United States
- Sponsor
- Mayo Clinic
Prostate Cancer
Low-Fat, High-Fiber Diet Compared to a Standard Diet in Treating Patients With Prostate Cancer
RATIONALE: A low-fat, high-fiber diet may slow the growth of prostate cancer. PURPOSE: Randomized phase II trial to compare the effectiveness of a low-fat, high-fiber diet with that of a standard diet in treating patients who…
- Trial name
- NCT00020995
- Testing
- therapeutic dietary intervention
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Cancer
RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
RATIONALE: Monoclonal antibodies, such as RAV12, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00101972
- Testing
- monoclonal antibody RAV12
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- MacroGenics
Prostate Cancer
Brachytherapy in Treating Patients With Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Giving radiation therapy through seeds implanted into the prostate may kill more tumor cells.
- Trial name
- NCT00003312
- Testing
- iodine I 125
- Where
- 258 sites in United States, Canada
- Volunteers
- 95 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer
Celecoxib Compared With No Treatment Before Surgery in Treating Patients With Localized Prostate Cancer
RATIONALE: Celecoxib may be an effective treatment for early stage prostate cancer. It is not yet known if celecoxib is more effective than no treatment before surgery for prostate cancer.
- Trial name
- NCT00022399
- Testing
- celecoxib
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer
Radiation Therapy Compared With No Further Treatment Following Surgery in Treating Patients With Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells and may be an effective treatment for prostate cancer.
- Trial name
- NCT00002511
- Testing
- low-LET photon therapy
- Where
- Belgium
- Volunteers
- 1,005 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Prostate Adenocarcinoma
Fluorescent Imaging of Nerves With Illuminare-1 During Surgery
This study will test the safety of using Illuminare-1 during standard surgery for prostate cancer. The study researchers will test increasing doses of Illuminare-1 to find the dose that makes the nerve structures fluoresce (light…
- Trial name
- NCT04983862
- Testing
- Illuminare-1, Karl Storz D-Light C photodynamic diagnostic (PDD)
- Where
- 6 sites in United States
- Volunteers
- 41 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Ann Arbor Stage I Lymphoma, Ann Arbor Stage II Lymphoma
- Trial name
- NCT05334069
- Testing
- Questionnaire Administration, Biospecimen Collection
- Where
- 751 sites in United States
- Volunteers
- 2,900 people, healthy volunteers welcome
- Sponsor
- Alliance for Clinical Trials in Oncology